GreenLight's mRNA vaccine nabs trial OK; Ratio reels in radiotherapy funds
GreenLight Biosciences will test its Covid-19 mRNA vaccine in Rwanda, the biotech said.
The RNA R&D and manufacturing company said the Rwanda FDA gave the go-ahead for a Phase I/II study testing the vaccine as a booster for people who have already been vaccinated against the pandemic virus.
“It is especially important to develop vaccines that are globally affordable and scalable. GreenLight’s efforts to initiate this clinical study in Rwanda show the company’s commitment to support Africa’s goal of affordable vaccine self-sufficiency,” said Mark Dybul, who chairs GreenLight’s scientific advisory board for human health, in a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.